Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714661 · ClinicalTrials.gov registry record · Phase 3
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Phase 3 study of Schizophrenia and Impaired Cognition, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 753
- Enrollment target
- 20
- Study locations
NCT01714661: Completed Phase 3 study of Schizophrenia and Impaired Cognition, sponsored by FORUM Pharmaceuticals.
NCT01714661 is a Phase 3 study of Schizophrenia and Impaired Cognition that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 753 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (247% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714661, a Phase 3 study of Schizophrenia and Impaired Cognition, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 753 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EVP-6124
Study Locations (20)
California
- - Anaheim
- - Bellflower
- - Costa Mesa
- - Culver City
- - Downey
- - Escondido
- - Los Angeles
- - Oceanside
- - Orange
- - San Diego
- - Torrance
Florida
- - Lauderhill
- - Miami
- - North Miami
- - Orange City
Arizona
- - Tucson
Georgia
- - Atlanta
Illinois
- - Chicago
Kansas
- - Wichita
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 753 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
What the finished NCT01714661 record still lists
NCT01714661 is an interventional study that assigns participants to a tested intervention. The registered 753 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (247% higher).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01714661 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01714661 about?
NCT01714661 is a clinical study titled "Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
What is the current status of trial NCT01714661?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 753 participants. The study started on 2012-10. Estimated completion is 2015-12.
What conditions does trial NCT01714661 study?
This clinical trial studies the following conditions: Schizophrenia, Impaired Cognition.
What interventions are being tested in trial NCT01714661?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01714661?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714661 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01714661's enrollment target sits among peer trials
753 17th of 315 higher than 299 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia